09:44 AM EST - Avant Technologies Inc : Along with its partner, Ainnova Tech, Inc., today announced that Apollo Hospitals and Ainnova have officially established a strategic collaboration that marks a significant step forward in the integration of artificial intelligence into disease detection and prediction. As part of this alliance, Ainnova has secured an exclusive license for several advanced AI algorithms, which have been rigorously validated with over 2.3 million data points and now form an integral part of Ainnova's Vision AI platform. These cutting-edge solutions enable the early and precise detection of conditions, such as cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 Diabetes, and lung abnormalities in CT scans and X-rays, including lung cancer. Avant Technologies Inc
shares O.AVAI are trading unchanged at $0.30.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=7000399228252942
